Regarding the preoperative evaluation of possible biomarkers, PMP patients with preoperative elevated tumor markers such as CEA and Ca 19-9 are at increased risk of developing recurrent disease despite aggressive therapy [15]. This evidence concerns the gene CEACAM5 and neoplasm.